All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, August 15, 2022
Home » Blogs » BioWorld Perspectives » Evidence and its Limits

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Cancer

Evidence and its Limits

Dec. 20, 2011
By Anette Breindl
No Comments

The evidence on evidence-based medicine speaks for itself. The approach is a vast improvement over everything that came before, and over current rival approaches. It’s often enough to give its practitioners a bit of hubris –which is why it’s so important to remember that evidence-based medicine can’t tell us everything we want to know, either.

Possible pitfalls and limitations of evidence-based medicine were on stark display at a press conference of the American Society of Hematology last week, where not one, but two studies reported results that were the opposite of what one might suspect from looking at one part of the evidence.

Ralph Meyer and colleagues at the NCIC Clinical Trials Group and the Eastern Cooperative Oncology Group demonstrated this rather starkly in a long-term study that compared chemotherapy alone to a radiation-based regimen for the treatment of early stage Hodgkin’s lymphoma. They found that the more intensive radiation-based treatment did decrease the recurrence of the Hodgkin’s disease itself. But over the course more than a decade, there were twice as many deaths in patients receiving radiation as those receiving chemotherapy.

The findings come with an additional twist: extensive radiation is no longer the standard treatment for Hodgkin’s lymphoma; newer regimens use less radiation, where the caveats of extensive radiation may or may not apply.

Meyer noted that there is no easy way out of this conundrum. “What we want is long-term data on the newest treatments, which is a mathematical impossibility.” But in the absence of such data, it is important to remember that “treatments that are given to patients have their own-long-term effects.”

And an editorial that appeared alongside the paper concluded that “these results support the view that the relapse rate is not a reliable surrogate for long-term survival, which is the most important treatment outcome” – and which is rarely looked at.

At the same press conference, the opposite relationship between initial impression and long-term effects was also on display. Updated information form a clinical trial of PCI-32765 showed that the Bruton’s tyrosine kinase inhibitor has ever-increasing effects against chronic lymphocytic leukemia – after an early sharp rise in blood levels of leukocytes when treatment is initiated.

Such a rise, of course, is the opposite of what an oncologist hopes for when treating a leukemia patient. Indeed, a few patients were taken off the drug early on, presumably because their doctors assumed they were progressing as their leukocyte counts rose. (And some patients do progress ‑ but nevertheless, response rates in one trial are now at 70 percent, up from about 25 percent a year ago.)

And so, modern medicine may be a marvel – but it’s good to bear in mind that whether our initial reaction to a given dataset might be “gee whiz” or “oh shoot, ” what those data mean is not always obvious at first glance.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 12, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 12, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing